Dr. Manuel Suarez, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 45
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 204
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME 47423
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 204
- Services billed
- 442
- Patients’ average age
- 80
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ipratropium-Albuterol (ipratropium/albuterol sulfate) Other prescribers in Miami, FL | 24 |
| Budesonide Other prescribers in Miami, FL | 14 |
| Montelukast Sodium Other prescribers in Miami, FL | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $588,948 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
Sanofi US Services Inc. · Completed · NCT06208306 - Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)
Sanofi US Services Inc. · Completed · NCT04701983 - Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
Sanofi US Services Inc. · Completed · NCT04456673 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Sanofi US Services Inc. · Recruiting · NCT07190209
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.